Less than 10% of people eligible to benefit from obesity jabs including Wegovy are able to get them, caution the World Health Organization as it releases its inaugural recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for more widespread and fairer access to this class of drugs.
Per estimates, over two billion could be obese by 2030 unless action is taken.
"Our new guidance affirms that excess weight is a long-term condition that can be treated with comprehensive and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are major hurdles to universal availability to the jabs that can aid individuals in losing substantial weight, says the agency.
Skinny Jab Shortage
Even in the current best projected outlook, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of the global need, according to the health organization.
The recommendation urges countries and companies to expand availability, via strategies including voluntary licensing.
The intellectual property rights on a key compound – the main ingredient of a leading brand – is scheduled to end in several countries in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs replicate a natural hormone to reduce digestion speed, curb appetite and enhance feelings of fullness so people reduce food intake.
Individuals commonly see weight reduction in the initial weeks of commencing the weekly injections.
Research points to people may put most of the weight back on within a year of halting the drug, when their typical appetite come back.
Being above a healthy weight raises your chance for contracting diseases, like type 2 diabetes, heart disease, stroke, and some malignancies.
Obesity affects individuals in every country and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.
